SB209509: Started a Phase I U.K. trial in 18 healthy volunteers, of whom 12 will receive drug and 6 placebo. The rising dose tolerance study will look at oral d

Vanguard Medica (Guilford, U.K.) Product: SB209509, 5HT1D partial receptor agonist Indication: Migraine Status: Started a Phase I U.K. trial in 18 healthy volunteers, of whom 12 will receive drug and...